We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MAGN:NYSEMagnera Corporation Analysis

Data as of 2026-08-23 - not real-time

$12.34

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Magnera Corporation is bullish at $12.34, with short-term averages leading the long-term ones. The last 30 days have lost 4.3%. With RSI at 45.5 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near $11.69 and resistance around $14.32.
Multiples put this in undervalued territory at a P/E of 7.6. Consensus targets land 25.6% above where the shares trade now. Revenue is growing at 2.1% on a -3.4% profit margin.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 49.1%, a beta of 1.19 and a maximum drawdown of 41.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.

Top Market Events

Magnera MAGN is scheduled to announce Q3 earnings results on Thursday, August 6th, before market open.Seeking Alpha17dMagnera Corporation MAGN Q3 2026 Earnings Call TranscriptThank you.10dMagnera Corporation: Executing But AbandonedMagnera is executing well post-merger, integrating operations, growing...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 12.21
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 12.21
  • Analyst targets imply +25.6% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Negative profit margin of -3.4%
  • Analyst targets imply +25.6% versus the current price
  • Negative return on equity of -10.4%

Key Metrics & Analysis

Financial Health

Revenue Growth2.10%
Profit Margin-3.41%
P/E Ratio7.6
ROE-10.43%
ROA2.27%
Debt/Equity192.82
P/B Ratio0.4
Op. Cash Flow$172.0M
Free Cash Flow$230.0M

Technical Analysis

TrendBullish
RSI45.5
Support$11.69
Resistance$14.32
MA 20$12.89
MA 50$12.78
MA 200$12.21
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Fair Value$43.32
Target Price$15.50
Upside/Downside25.61%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.19
Volatility49.15%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.